StockData
Oncotelic Therapeutics, Inc. logo

Oncotelic Therapeutics, Inc. (OTLC) stock

OTLCOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.02+0.00 (+11.45%)

Close on Oct 19, 2026Market cap $8.66MP/E 0.0Yield –

Oncotelic Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Oncotelic Therapeutics's profit margin for the twelve months ending Dec 31, 2023 was -11290.1%. For fiscal 2023 it was -11290.1%, against -545.9% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 2023-11290.1%−10744.3
FY2020Dec 31, 2020-545.9%+8166.8
FY2013Dec 31, 2013-8712.6%−3533.8
FY2012Dec 31, 2012-5178.8%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026155.3%–
Q3 FY2023Sep 30, 2023164.7%–
Q2 FY2020Jun 30, 202041.6%–
Q1 FY2020Mar 31, 2020-1366.5%–

More Oncotelic Therapeutics figures

See a number that looks wrong?